Surv BioPharma raises ¥1.5 billion in Series B first close
KII’s impact fund led financing for clinical and nonclinical development of cancer therapies.
Surv BioPharma completed a ¥1.5 billion Series B first close, which it detailed on 11 November 2025. Fujita TT Impact Fund I had announced its investment on 10 October, ahead of the company’s full-round announcement.
KII No.3 Impact Fund led the financing. Other participants included NVCC Fund 10, QB Fund II, Fujita TT Impact Fund I and Higin Venture Fund No. 3 Investment Limited Partnership.
Returning investors also participated through Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II and Kagoshima Value Up Investment Limited Partnership.
The Kagoshima University spinout plans to use the proceeds for nonclinical development, manufacturing investigational medicines and overseas clinical development of its oncolytic-virus programmes.
Use of funds
Nonclinical development, manufacturing investigational medicines and international clinical development of oncolytic-virus therapies